Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Computer-Aided Cell Analysis Enables Faster Diagnosis of Blood Diseases

By LabMedica International staff writers
Posted on 11 Aug 2023

Blood disorders are frequently characterized by alterations in the quantities and shapes of red and white blood cells. More...

Traditional methods for diagnosing the disease involves examining blood smears on a slide under a microscope, although evaluating these changes can be challenging even for experienced professionals, as subtle alterations can affect only a small fraction of the tens of thousands of visible cells. Consequently, distinguishing between diseases is not always simple. For instance, the visible changes in the blood of individuals with myelodysplastic syndrome (MDS), an early form of leukemia, often resemble those seen in less harmful types of anemia. The definitive diagnosis of MDS requires more invasive procedures such as bone marrow biopsies and molecular genetic testing.

Scientists from the German Cancer Research Center (DKFZ, Heidelberg, Germany) and the Cambridge Stem Cell Institute (Cambridge, UK) have now developed an artificial intelligence (AI) system capable of identifying and characterizing white and red blood cells in microscopic images of blood samples. This algorithm, named Haemorasis, aids physicians in diagnosing blood disorders and is publicly accessible as an open-source tool for research purposes. Initially, the scientists trained Haemorasis to recognize cell morphology using over half a million white blood cells and millions of red blood cells from more than 300 individuals with various blood disorders (including different forms of anemia and MDS).

Leveraging this acquired knowledge, Haemorasis can now propose diagnoses for blood disorders and even differentiate genetic subtypes of these conditions. Additionally, the algorithm uncovers significant associations between specific cell shapes and diseases, a task complicated by the sheer volume of cells involved. Haemorasis underwent testing on three distinct patient groups to confirm its efficacy across diverse test centers and blood count scanner systems. Tailored for hematology diagnostics, Haemorasis aids in providing a more accurate initial diagnosis of blood disorders, which is an essential step in identifying patients who may require more invasive procedures like bone marrow tests or genetic analysis. Ongoing studies will explore the potential limitations of the method.

"Automated cell analysis with Haemorasis could complement routine diagnosis of blood disorders in the future. So far, the algorithm has only been trained on specific diseases - but we still see great potential in this approach," said Moritz Gerstung of DKFZ.

Related Links:
German Cancer Research Center
Cambridge Stem Cell Institute


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.